Form 4: Director Janet Napolitano Sells Vir Biotechnology Shares

Director Janet Napolitano sold 3,200 shares of Vir Biotechnology, Inc. common stock at a price of $9.45 per share.

Summary

• Director Janet Napolitano executed a sale of 3,200 shares of Vir Biotechnology (VIR) common stock.
• The transaction occurred on June 1, 2026, at a price of $9.45 per share.
• Following this transaction, the reporting person retains beneficial ownership of 21,216 shares.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on June 27, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing 10b5-1 plan, which is a standard mechanism for liquidity.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on sudden non-public information.

Negatives

• The sale represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock performance, though this was a pre-planned sale.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice for corporate directors and typically does not signal a change in fundamental company strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to divest shares while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Vir Biotechnology, VIR, Insider Trading, Form 4, Janet Napolitano, Biotech